• Teva Pharmaceutical Industries reported its 2025 results on January 28, 2026, with revenue rising to US$17.26 billion and net income improving to US$1.41 billion, alongside continued momentum in branded drugs like AUSTEDO, UZEDY, and AJOVY.
• The earnings release underscored Teva’s ongoing shift from a primarily generics-focused business toward higher-margin innovative medicines, supported by cost savings initiatives and late-stage pipeline progress.
• We’ll now examine how Teva’s improving branded portfolio performance and pipeline advancement shape the company’s investment narrative over the coming years.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

What Is Teva Pharmaceutical Industries' Investment Narrative?

For Teva to make sense in a portfolio today, you really have to buy into its pivot from a low-margin generics giant to a more focused branded and specialty pharma company, with AUSTEDO, UZEDY and AJOVY doing more of the heavy lifting. The 2025 results, with revenue at about US$17.26 billion and a swing to US$1.41 billion in net income, support that story and help explain the strong share price run over the past year. At the same time, the stock now trades on a richer earnings multiple, so expectations around pipeline milestones such as the late-stage programs and execution on the “Pivot to Growth” cost savings feel more important in the near term. The latest earnings beat and reiterated guidance help de-risk that narrative somewhat, but do not remove the key pressure points, including balance sheet leverage, generics headwinds and future pricing on AUSTEDO as 2027 approaches.

However, one risk in particular could catch investors off guard if sentiment turns.
Teva Pharmaceutical Industries' shares have been on the rise but are still potentially undervalued by 41%. Find out what it's worth.

Exploring Other Perspectives

Thirteen fair value estimates from the Simply Wall St Community span roughly US$26 to US$57 per share, reflecting very different expectations. Set that against Teva’s richer earnings multiple and elevated balance sheet risk, and it becomes clear why many readers look at several viewpoints before deciding how much of the recent turnaround they are comfortable underwriting.

Explore 13 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth as much as 70% more than the current price!

Build Your Own Teva Pharmaceutical Industries Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.